Back to Studies

IMPAACT 2022

Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV

Study Status

In Development

Locality

United States

DAIDS Number

38631

Summary

IMPAACT 2022 is a Phase II, multi-center, open-label, non-comparative study to evaluate the effectiveness, feasibility, and pharmacokinetics of long-acting injectable cabotegravir and rilpivirine in non-adherent HIV-1 infected youth. This study will assess the rate of virologic control of these long acting antiretroviral medications among 70 non-adherent youth age 13 to <25 years.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...